


## Trends in annual price for disease-modifying therapies for multiple sclerosis; 1993 to 2023



Drug (manufacturer)	1 Year Change*	Annual Price 2023
<b>Self-administered Injections</b>		
Betaseron (Bayer)	7.1%	\$119,610
Avonex (Biogen)	5.5%	\$101,796
Rebif (EMD Serono)	4.0%	\$119,973
Extavia (Novartis)	15.4%	\$93,566
Plegridy (Biogen)	5.5%	\$101,796
Kesimpta (Novartis)	9.1%	\$97,969
<b>Glatiramer Acetate</b>		
Copaxone 20 (Teva)	0.0%	\$86,554
Copaxone 40 (Teva)	0.0%	\$75,816
Glatopa (Sandoz)	0.0%	\$18,250
Glatopa 40 (Sandoz)	0.0%	\$19,500
Glat Acet (Mylan)	0.0%	\$23,725
Glat Acet 40 (Mylan)	0.0%	\$25,350
<b>S1P Receptor Modulators</b>		
Gilenya (Novartis)	9.1%	\$126,812
Mayzent (Novartis)	9.1%	\$112,346
Zeposia (Celgene)	6.0%	\$99,549
Ponvory (Janssen)	0.0%	\$103,660
Fingolimod (generic)**	NA	\$3,893
<b>Fumarates</b>		
Tecfidera (Biogen)	8.1%	\$108,896
Vumerity (Biogen)	4.0%	\$98,064
Bafiertam (Banner)	5.0%	\$76,192
Dimethyl fumarate (generic)**	0.0%	\$2,738
<b>Other Oral DMTs</b>		
Aubagio (Genzyme)	6.0%	\$109,862
Mavenclad (EMD Serono)	6.0%	\$127,986
<b>Infusions</b>		
Tysabri (Biogen)	4.5%	\$106,722
Lemtrada (Genzyme)	4.7%	\$92,496
Ocrevus (Genentech)	5.5%	\$75,102
Briumvi (TG Therapeutics)	NA	\$59,000

Notes: Annual price estimated from wholesale acquisition costs (First Databank)  
 Market entrance date in parenthesis  
 Dashed line is projected annual price of Betaseron assuming only inflationary increases in price (CPI)  
 Lemtrada is based on four 12 mg vials (Package insert dosing: 12 mg/day (5 vials) for five consecutive days in first year; 12 mg/day (3 vials) for three days in year 2);  
 Briumvi is based on maintenance dose of 450 mg (3 vials) twice a year;  
 \*2021 to 2022 (January); \*\*Generic, lowest WAC reported